LENSAR Inc
NASDAQ:LNSR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
LENSAR Inc
Net Change in Cash
LENSAR Inc
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
LENSAR Inc
NASDAQ:LNSR
|
Net Change in Cash
-$3.3m
|
CAGR 3-Years
42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Net Change in Cash
$1.5B
|
CAGR 3-Years
87%
|
CAGR 5-Years
0%
|
CAGR 10-Years
27%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Net Change in Cash
-$119.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
Net Change in Cash
$359m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-14%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Net Change in Cash
$906m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
24%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Net Change in Cash
$1.3B
|
CAGR 3-Years
66%
|
CAGR 5-Years
24%
|
CAGR 10-Years
28%
|
|
LENSAR Inc
Glance View
LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. The company is headquartered in Orlando, Florida and currently employs 110 full-time employees. The company went IPO on 2020-09-21. The firm is focused on designing, developing, and marketing femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company has developed the LENSAR Laser System to provide an alternative laser cataract treatment tool that allows the surgeon to better address astigmatism and improve visual outcomes. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The company is also developing an integrated cataract treatment system, ALLY, which is designed to combine its existing femtosecond laser technology with phacoemulsification system into a single unit and allow surgeons to perform each of the critical steps in a cataract procedure in a single operating room using this device.
See Also
What is LENSAR Inc's Net Change in Cash?
Net Change in Cash
-3.3m
USD
Based on the financial report for Dec 31, 2025, LENSAR Inc's Net Change in Cash amounts to -3.3m USD.
What is LENSAR Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
42%
Over the last year, the Net Change in Cash growth was 25%. The average annual Net Change in Cash growth rates for LENSAR Inc have been 42% over the past three years .
